NERVTAG: Antiviral drug resistance and the use of directly acting antiviral drugs (DAAs) for COVID-19, 8 December 2021
Paper prepared by the New and Emerging Respiratory Virus Threats Advisory Group (NERVTAG).
Documents
Details
Paper prepared by New and Emerging Respiratory Virus Threats Advisory Group (NERVTAG) on antiviral drug resistance and use of directly acting antiviral drugs (DAAs). It was considered at SAGE 98 on 7 December 2021 and updated 8 December 2021. As new evidence or data emerges, SAGE updates its advice accordingly.
The following members of NERVTAG authored this paper: Peter Horby; Wendy Barclay; Julian A.Hiscox; Meera Chand; Judith Breuer; Emma Sherwood and Andrew Owen.
These documents are released as pre-print publications that have provided the government with rapid evidence during an emergency. These documents have not been peer-reviewed and there is no restriction on authors submitting and publishing this evidence in peer-reviewed journals.